166 related articles for article (PubMed ID: 36830214)
1. Pulmonary Pharmacokinetic and Pharmacodynamic Evaluation of Ampicillin/Sulbactam Regimens for Pneumonia Caused by Various Bacteria, including
Onita T; Ikawa K; Ishihara N; Tamaki H; Yano T; Naora K; Morikawa N
Antibiotics (Basel); 2023 Feb; 12(2):. PubMed ID: 36830214
[TBL] [Abstract][Full Text] [Related]
2. Population pharmacokinetic-pharmacodynamic target attainment analysis of sulbactam in patients with impaired renal function: dosing considerations for Acinetobacter baumannii infections.
Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Morikawa N; Takeda Y
J Infect Chemother; 2015 Apr; 21(4):284-9. PubMed ID: 25638291
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic Evaluation of Ampicillin-sulbactam in Pediatric Patients Using Plasma and Urine Data.
Onita T; Ikawa K; Ishihara N; Tamaki H; Yano T; Naora K; Morikawa N
Pediatr Infect Dis J; 2022 May; 41(5):411-416. PubMed ID: 35195566
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/pharmacodynamic evaluation of sulbactam against Acinetobacter baumannii in in vitro and murine thigh and lung infection models.
Yokoyama Y; Matsumoto K; Ikawa K; Watanabe E; Shigemi A; Umezaki Y; Nakamura K; Ueno K; Morikawa N; Takeda Y
Int J Antimicrob Agents; 2014 Jun; 43(6):547-52. PubMed ID: 24796218
[TBL] [Abstract][Full Text] [Related]
5. Prostatic Pharmacokinetic/Pharmacodynamic Evaluation of Ampicillin-Sulbactam for Bacterial Prostatitis and Preoperative Prophylaxis.
Onita T; Ikawa K; Nakamura K; Nishikawa G; Kobayashi I; Ishihara N; Tamaki H; Yano T; Naora K; Morikawa N
J Clin Pharmacol; 2021 Jun; 61(6):820-831. PubMed ID: 33314138
[TBL] [Abstract][Full Text] [Related]
6. Development of Modernized Acinetobacter baumannii Susceptibility Test Interpretive Criteria for Recommended Antimicrobial Agents Using Pharmacometric Approaches.
Lepak AJ; Trang M; Hammel JP; Sader HS; Bhavnani SM; VanScoy BD; Pogue JM; Ambrose PG; Andes DR;
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0145222. PubMed ID: 36946729
[TBL] [Abstract][Full Text] [Related]
7. In vitro pharmacodynamics of human-simulated exposures of ampicillin/sulbactam, doripenem and tigecycline alone and in combination against multidrug-resistant Acinetobacter baumannii.
Housman ST; Hagihara M; Nicolau DP; Kuti JL
J Antimicrob Chemother; 2013 Oct; 68(10):2296-304. PubMed ID: 23710070
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics and Dosing Simulations of Ampicillin and Sulbactam in Hospitalised Adult Patients.
Setiawan E; Cotta MO; Abdul-Aziz MH; Widjanarko D; Sosilya H; Lukas DL; Wallis SC; Parker S; Roberts JA
Clin Pharmacokinet; 2023 Apr; 62(4):573-586. PubMed ID: 36853585
[TBL] [Abstract][Full Text] [Related]
9. Population pharmacokinetics of ampicillin and sulbactam in patients with community-acquired pneumonia: evaluation of the impact of renal impairment.
Soto E; Shoji S; Muto C; Tomono Y; Marshall S
Br J Clin Pharmacol; 2014 Mar; 77(3):509-21. PubMed ID: 24102758
[TBL] [Abstract][Full Text] [Related]
10. Population pharmacokinetics and Monte Carlo simulations of sulbactam to optimize dosage regimens in patients with ventilator-associated pneumonia caused by Acinetobacter baumannii.
Jaruratanasirikul S; Nitchot W; Wongpoowarak W; Samaeng M; Nawakitrangsan M
Eur J Pharm Sci; 2019 Aug; 136():104940. PubMed ID: 31132402
[TBL] [Abstract][Full Text] [Related]
11. Population Pharmacokinetics and Pharmacodynamics Modeling To Optimize Dosage Regimens of Sulbactam in Critically Ill Patients with Severe Sepsis Caused by Acinetobacter baumannii.
Jaruratanasirikul S; Wongpoowarak W; Wattanavijitkul T; Sukarnjanaset W; Samaeng M; Nawakitrangsan M; Ingviya N
Antimicrob Agents Chemother; 2016 Dec; 60(12):7236-7244. PubMed ID: 27671056
[TBL] [Abstract][Full Text] [Related]
12.
O'Donnell J; Tanudra A; Chen A; Miller AA; McLeod SM; Tommasi R
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0031223. PubMed ID: 38092676
[TBL] [Abstract][Full Text] [Related]
13. Semi-mechanistic PK/PD modelling of meropenem and sulbactam combination against carbapenem-resistant strains of Acinetobacter baumannii.
Mohd Sazlly Lim S; Heffernan AJ; Zowawi HM; Roberts JA; Sime FB
Eur J Clin Microbiol Infect Dis; 2021 Sep; 40(9):1943-1952. PubMed ID: 33884516
[TBL] [Abstract][Full Text] [Related]
14. Model-Informed Clinical Practice - Determining an Appropriate Ampicillin-Sulbactam Redosing Regimen in Surgical Patients by Utilizing Population Pharmacokinetics and Target Attainment Analysis.
Reeder JA; O'Sullivan CT; Xu M; Wu N; Ince D; Rogers WK; An G
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0124822. PubMed ID: 36920230
[TBL] [Abstract][Full Text] [Related]
15. Combined PK/PD Index May Be a More Appropriate PK/PD Index for Cefoperazone/Sulbactam against
Zhou Y; Zhang J; Chen Y; Wu J; Guo B; Wu X; Zhang Y; Wang M; Ya R; Huang H
Antibiotics (Basel); 2022 May; 11(5):. PubMed ID: 35625347
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses Evaluating Omadacycline Dosing Regimens for the Treatment of Patients with Community-Acquired Bacterial Pneumonia Arising from Streptococcus pneumoniae and Haemophilus influenzae.
Bhavnani SM; Hammel JP; Lakota EA; Trang M; Bader JC; Bulik CC; VanScoy BD; Rubino CM; Huband MD; Friedrich L; Steenbergen JN; Ambrose PG
Antimicrob Agents Chemother; 2023 Apr; 67(4):e0221321. PubMed ID: 36946741
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic-Pharmacodynamic Target Attainment Analyses as Support for Meropenem-Vaborbactam Dosing Regimens and Susceptibility Breakpoints.
Bhavnani SM; Trang M; Griffith DC; Lomovskaya O; Hammel JP; Loutit JS; Cammarata SK; Dudley MN; Ambrose PG; Rubino CM
Antimicrob Agents Chemother; 2022 Dec; 66(12):e0213021. PubMed ID: 36374023
[TBL] [Abstract][Full Text] [Related]
18. Colistin plus Sulbactam or Fosfomycin against Carbapenem-Resistant
Saelim W; Changpradub D; Thunyaharn S; Juntanawiwat P; Nulsopapon P; Santimaleeworagun W
Infect Chemother; 2021 Mar; 53(1):128-140. PubMed ID: 34409786
[TBL] [Abstract][Full Text] [Related]
19.
O'Donnell J; Tanudra A; Chen A; Newman J; McLeod SM; Tommasi R
Antimicrob Agents Chemother; 2024 Jan; 68(1):e0080023. PubMed ID: 38092671
[TBL] [Abstract][Full Text] [Related]
20. Tracking Cefoperazone/Sulbactam Resistance Development In vivo in A. baumannii Isolated from a Patient with Hospital-Acquired Pneumonia by Whole-Genome Sequencing.
Liu X; Zheng H; Zhang W; Shen Z; Zhao M; Chen Y; Sun L; Shi J; Zhang J
Front Microbiol; 2016; 7():1268. PubMed ID: 27594850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
